Pain, Postoperative

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company’s novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. “We are leveraging our existing know-how and intellectual property to target different pain indications and methods of delivery in an efficient and synergistic manner. We are taking advantage of the extensive pre-clinical and Phase I studies performed with CC8464 demonstrating strong efficacy in a wide variety of preclinical models and no dose limiting tolerability concerns in four Phase I trials,” said Frank Knuettel, Chief Executive Officer. Eric Lang, Chief Medical Officer further commented, “Of the various sodium channel targets, NaV1.7 is the most genetically validated for the treatment of pain. The over expression of NaV1.7 activity leads to Erythromelalgia, one of the most severe types of pain described in humans, whereas over expression of NaV1.8 leads to mild-moderate pain. We anticipate that our injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain could be an excellent and potent analgesic.” The Company believes there are strong synergies between the programs and is building a suite of related products to address multiple different types of pain and methods of delivery, with a drug that has shown no addictive properties in 4 Phase I trials. With these programs, the Company hopes to reduce usage of opioids and other sub-optimal drugs in various indications and expects to be able to take advantage of certain NOPAIN Act provisions if the drugs are approved by the FDA. About Chromocell Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and acute and chronic eye pain. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the amount of shares of Common Stock to be repurchased under the Repurchase Plan, if any, (ii) the Company’s belief that its Common Stock is undervalued, (iii) the Company’s belief that its Common Stock is an attractive investment at its current price, (iv) the Company’s ability to conduct repurchases in accordance with applicable laws and regulations, (v) our ability to enhance stockholder value and (vi) the impact of laws and regulations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. For Investor Inquiries:Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com

The grant from the NIH HEAL Initiative® will support the development and clinical advancement of Neural Ice™, a non-opioid, injectable solution offering long-lasting pain relief. CAMBRIDGE, Mass., Oct. 24, 2024 /PRNewswire/ -- Brixton Biosciences, a clinical-stage life sciences company, today announced it has been awarded first-year funding of a $2 million grant from the National Institutes of Health (NIH) through the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®. The grant (No. R44AR084998) will support Brixton's ongoing development of Neural Ice™, an injectable, drug-free pain management technology designed to provide long-lasting relief from chronic and post-operative pain. This funding is part of the NIH's efforts to address the opioid crisis by advancing scientific solutions that reduce reliance on opioids for pain treatment. The NIH HEAL Initiative is a nationwide effort to address the opioid public health crisis, funding research projects that explore innovative approaches to understanding, managing, and treating pain, as well as preventing opioid misuse and addiction. Brixton Biosciences' Neural Ice™ aligns with this mission as it represents a novel, drug-free alternative to opioids for pain management. "Our award from the NIH HEAL Initiative is a significant step forward in addressing the urgent need for non-opioid pain management solutions," said Sameer Sabir, CEO and Co-Founder of Brixton Biosciences. "This funding will further advance Neural Ice, helping us bring safer, non-addictive options to a broad array of patients who suffer from chronic and post-surgical pain. We're proud to contribute to the fight against opioid misuse and addiction. We truly believe Neural Ice will change the landscape of pain relief." The NIH grant will enable Brixton to refine Neural Ice™ and accelerate its clinical application, expanding its development to indications beyond the initial study focused on chronic knee pain. By focusing on non-pharmacological treatments, this initiative supports the broader healthcare mission of reducing opioid dependency while improving patient outcomes. Brixton's award from the NIH HEAL Initiative underscores a shared commitment to solving critical public health issues. The collaboration advances Brixton's groundbreaking pain management research while contributing to a broader effort to stem the tide of opioid misuse across the country. About Brixton Biosciences: Brixton Biosciences, a spin-out from Massachusetts General Brigham, is a clinical-stage life sciences company that develops novel therapies for treating pain. Its leadership team comprises experienced managers and key medical advisors, enabling a patient-centric strategy driven by the best of the best. Backed by deep research, the company addresses crucial unmet needs in the field of pain management, which has historically been dominated by systemic medicine. Brixton Biosciences' innovative therapeutics, such as its novel Neural Ice™, have the potential to provide pain relief in a single and easy drug-free injectable that is a non-addictive, locally targeted, and comparatively long-lasting solution. Media Contact: Anushka Teckwani [email protected] SOURCE Brixton Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN LUIS OBISPO, Calif., Oct. 15, 2024 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a recognized global leader in post-surgical adhesion prevention, today announced it will attend the European Society of Gynecological Endoscopy (ESGE) 33rd annual congress October 27-30 in Marseille, France. The Company will showcase its innovative Oxiplex/IU® and Oxiplex/AP® adhesion barrier gels designed to reduce the formation of adhesions following intrauterine and abdominal/pelvic related surgical procedures. Since its foundation, ESGE has aimed to encourage the exchange of clinical experience, scientific thought and investigation among gynecological practitioners in minimally invasive techniques. FzioMed's synthetic adhesion barrier products, based on the Company's patented dual-polymer technology and more than 20 years of clinical use, provide a temporary physical barrier between tissues helping prevent the formation of adhesions, reducing the incidence of postoperative pain and other complications. For intrauterine and abdominal/pelvic related surgical procedures, Oxiplex/IU and Oxiplex/AP gels and their unique applicators offer ease of use combined with proven safety and clinical efficacy. Patrick Bellelis, MD, PhD, endometriosis specialist and minimally invasive gynecologic surgeon at the University of Sao Paolo, Brazil, will be presenting two video lectures on Tuesday, October 29 starting at 15:00 CET (UTC+01:00) titled: "Challenging Case of Deep Endometriosis with Significant Involvement of the Rectovaginal Septum" and "Postoperative Endometriosis Second Look after Application of Anti-Adhesion Viscoelastic Gel." Prof. Bellelis will also be available at FzioMed's exhibitor booth (Booth #A4) periodically throughout the congress to speak about his clinical experience with the Oxiplex family of adhesion barrier gels. "Even with the best surgical technique, postoperative adhesions can form following abdominal, pelvic, and gynecological procedures – from hernia and bariatric procedures to hysterectomy, endometriosis, and other tubal and ovarian surgeries," stated Stephanie Cortese, Senior Vice President of Science and Technology. "These adhesions can cause a variety of complications including chronic pelvic pain, small bowel obstructions, infertility, and scarring that can complicate future surgery." FzioMed's Adhesion Barrier Gels are provided sterile and ready to use with specialized applicators for hysteroscopic or laparoscopic use that allow for ease of application while the clear gel formula maintains local visibility. No special storage, refrigeration, mixing, or handling is required. Oxiplex/IU and Oxiplex/AP gels do not migrate after application as their unique viscosity is flowable yet remains where applied. FzioMed's portfolio of adhesion barrier products have been available since 2002 and have been used in nearly 1 million procedures worldwide. About FzioMed, Inc. Pioneering biomaterials since 1996, FzioMed is a vertically integrated medical device company focused exclusively on preserving surgical excellence in spine, orthopedic, abdominal/pelvic and gynecological procedures. FzioMed develops, manufactures, and commercializes surgical biomaterials used by clinicians as adhesion barriers to improve surgical outcomes and is a recognized global leader in post-surgical adhesion prevention. FzioMed's synthetic, absorbable gel formulations are based on the Company's patented dual-polymer technology platform that provide a temporary, mechanical separation of tissues during the body's natural healing process – reducing adhesion formation. FzioMed's portfolio of adhesion barrier products are marketed in more than 70 countries under various brand names and have been used clinically since 2002 in nearly 1 million procedures worldwide. Visit fziomed.com to learn more about FzioMed and our industry-leading products. SOURCE FzioMed WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED